Lloyd A Gall

Array ( [id] => 15683695 [patent_doc_number] => 20200096511 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-26 [patent_title] => SAMPLE DESTRUCTION VALIDATION SYSTEM AND METHODS [patent_app_type] => utility [patent_app_number] => 16/576415 [patent_app_country] => US [patent_app_date] => 2019-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8762 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16576415 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15831947 [patent_doc_number] => 20200131255 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-30 [patent_title] => METHODS OF TREATING NEURODEGENERATIVE DISEASES [patent_app_type] => utility [patent_app_number] => 16/576249 [patent_app_country] => US [patent_app_date] => 2019-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23725 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16576249 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16353130 [patent_doc_number] => 10793631 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-10-06 [patent_title] => Human PAC1 antibodies [patent_app_type] => utility [patent_app_number] => 16/572271 [patent_app_country] => US [patent_app_date] => 2019-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 39652 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16572271 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18421600 [patent_doc_number] => 20230176064 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => METHODS AND KITS FOR DETECTING TARGET SUBSTANCES [patent_app_type] => utility [patent_app_number] => 17/040821 [patent_app_country] => US [patent_app_date] => 2019-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33724 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17040821 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18503558 [patent_doc_number] => 11701348 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2023-07-18 [patent_title] => Psilocybin compositions [patent_app_type] => utility [patent_app_number] => 16/552498 [patent_app_country] => US [patent_app_date] => 2019-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5461 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16552498 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19211788 [patent_doc_number] => 12000844 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-04 [patent_title] => Diagnostic drug and diagnostic method for Alzheimer's disease [patent_app_type] => utility [patent_app_number] => 17/265805 [patent_app_country] => US [patent_app_date] => 2019-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 16 [patent_no_of_words] => 23760 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 306 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17265805 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15435461 [patent_doc_number] => 20200031914 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => ANTIBODIES RECOGNIZING MEDIN [patent_app_type] => utility [patent_app_number] => 16/530551 [patent_app_country] => US [patent_app_date] => 2019-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28586 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16530551 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16564290 [patent_doc_number] => 10889650 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-12 [patent_title] => Agent, uses and methods for treatment [patent_app_type] => utility [patent_app_number] => 16/521279 [patent_app_country] => US [patent_app_date] => 2019-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 42 [patent_no_of_words] => 28907 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16521279 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18667566 [patent_doc_number] => 11774457 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-03 [patent_title] => Identification and analysis of protein biomarkers [patent_app_type] => utility [patent_app_number] => 16/506639 [patent_app_country] => US [patent_app_date] => 2019-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 60 [patent_figures_cnt] => 106 [patent_no_of_words] => 23746 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16506639 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15432465 [patent_doc_number] => 20200030415 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => COMBINATION THERAPY WITH CGRP ANTAGONISTS AND CLOSTRIDIAL DERIVATIVES [patent_app_type] => utility [patent_app_number] => 16/503740 [patent_app_country] => US [patent_app_date] => 2019-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11777 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16503740 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16854937 [patent_doc_number] => 20210155682 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-27 [patent_title] => COMPOSITIONS AND METHODS FOR REDUCTION OF LIPOPROTEIN A FORMATION AND TREATMENT OF AORTIC VALVE SCLEROSIS AND AORTIC STENOSIS [patent_app_type] => utility [patent_app_number] => 17/257055 [patent_app_country] => US [patent_app_date] => 2019-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15600 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17257055 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18028952 [patent_doc_number] => 11512125 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-29 [patent_title] => Antibodies for the treatment of synucleinopathies and neuroinflammation [patent_app_type] => utility [patent_app_number] => 17/255776 [patent_app_country] => US [patent_app_date] => 2019-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 54 [patent_no_of_words] => 23213 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17255776 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15963137 [patent_doc_number] => 20200165320 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => IN VITRO GLYCOENGINEERING OF ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/447093 [patent_app_country] => US [patent_app_date] => 2019-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18810 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16447093 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16389620 [patent_doc_number] => 20200330561 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-22 [patent_title] => COMPOSITION FOR TREATMENT OF FACIAL NERVE PALSY [patent_app_type] => utility [patent_app_number] => 16/433797 [patent_app_country] => US [patent_app_date] => 2019-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3323 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16433797 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15175459 [patent_doc_number] => 20190358321 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-28 [patent_title] => USE OF SEMAPHORIN-4D BINDING MOLECULES FOR MODULATION OF BLOOD BRAIN BARRIER PERMEABILITY [patent_app_type] => utility [patent_app_number] => 16/433496 [patent_app_country] => US [patent_app_date] => 2019-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21002 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16433496 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16290128 [patent_doc_number] => 10766964 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-08 [patent_title] => Compositions and methods for treating and preventing inflammation [patent_app_type] => utility [patent_app_number] => 16/422273 [patent_app_country] => US [patent_app_date] => 2019-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 86 [patent_figures_cnt] => 149 [patent_no_of_words] => 29691 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16422273 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16962872 [patent_doc_number] => 20210214371 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-15 [patent_title] => Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates [patent_app_type] => utility [patent_app_number] => 17/056270 [patent_app_country] => US [patent_app_date] => 2019-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19174 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17056270 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15117209 [patent_doc_number] => 20190345237 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-14 [patent_title] => ANTIBODY-BASED THERAPY OF TRANSTHYRETIN (TTR) AMYLOIDOSIS AND HUMAN-DERIVED ANTIBODIES THEREFOR [patent_app_type] => utility [patent_app_number] => 16/413335 [patent_app_country] => US [patent_app_date] => 2019-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48120 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16413335 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16727864 [patent_doc_number] => 20210095011 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-01 [patent_title] => IMPROVED ANTI-FIBRONECTIN EDA ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/051804 [patent_app_country] => US [patent_app_date] => 2019-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16879 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17051804 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17931132 [patent_doc_number] => 20220326257 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-13 [patent_title] => DETECTION OF AUTOANTIBODIES AGAINST DEIMINATED PROTEIN EPITOPES ASSOCIATED WITH BRAIN OXYGEN DEPRIVATION [patent_app_type] => utility [patent_app_number] => 17/051857 [patent_app_country] => US [patent_app_date] => 2019-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22330 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17051857 [rel_patent_id] =>[rel_patent_doc_number] =>)